Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study

The Lancet Psychiatry

Volumn 3, Issue 10, 2016, Pages 947-953

  Schoeler, Tabea ^a   Petros, Natalia ^a   Di Forti, Marta ^a   Klamerus, Ewa ^a   Foglia, Enrico ^a   Ajnakina, Olesya ^a   Gayer Anderson, Charlotte ^a   Colizzi, Marco ^a   Quattrone, Diego ^a   Behlke, Irena ^a   Shetty, Sachin ^a   McGuire, Philip ^a   David, Anthony S ^a   Murray, Robin ^a   Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; ILLICIT DRUG;

ADULT; ARTICLE; CANNABIS USE; CONTROLLED STUDY; CRISIS INTERVENTION; ENGLAND; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL HEALTH SERVICE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; TELEPHONE INTERVIEW; ADOLESCENT; AGED; CANNABIS SMOKING; MIDDLE AGED; ONSET AGE; PROSPECTIVE STUDY; PSYCHOTIC DISORDERS; RECURRENT DISEASE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RECURRENCE; RISK FACTORS; YOUNG ADULT;

EID: 84994618744     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)30188-2     Document Type: Article

References (25)

1. 1 Moore, THM, Zammit, S, Lingford-Hughes, A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (2007), 319–328.
2. 2 Stepniak, B, Papiol, S, Hammer, C, et al. Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. Lancet Psychiatry 1 (2014), 444–453.
3. 3 Moore, E, Mancuso, SG, Slade, T, Galletly, CA, Castle, DJ, The impact of alcohol and illicit drugs on people with psychosis: The second Australian national survey of psychosis. Aust N Z J Psychiatry 46 (2012), 864–878.
4. 4 Patel, R, Wilson, R, Jackson, R, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open, 6, 2016, e009888.
5. 5 González-Pinto, A, Alberich, S, Barbeito, S, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 37 (2011), 631–639.
6. 6 Hinton, M, Edwards, J, Elkins, K, et al. Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Interv Psychiatry 1 (2007), 259–266.
7. 7 Schoeler, T, Monk, A, Sami, MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3 (2016), 215–225.
8. 8 Bhattacharyya, S, Fusar-Poli, P, Borgwardt, S, et al. Modulation of mediotemporal and ventrostriatal function in humans by {Delta} 9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66 (2009), 442–451.
9. 9 D'Souza, DC, Abi-Saab, WM, Madonick, S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57 (2005), 594–608.
10. 10 Di Forti, M, Marconi, A, Carra, E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2 (2015), 233–238.
11. 11 Wiersma, D, Nienhuis, FJ, Slooff, CJ, Giel, R, Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 24 (1998), 75–85.
12. 12 Knapp, M, Locklear, J, Järbrink, K, Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Curr Med Res Opin 25 (2009), 1593–1603.
13. 13 Alvarez-Jimenez, M, Priede, A, Hetrick, S, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139 (2012), 116–128.
14. 14 WHO. International statistical classification of diseases and related health problems, 2004, World Health Organization, Geneva.
15. 15 Rubin, DB, Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2 (2001), 169–188.
16. 16 Leucht, S, Tardy, M, Komossa, K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379 (2012), 2063–2071.
17. 17 Hides, L, Dawe, S, Kavanagh, D, Young, RM, Psychotic symptom and cannabis relapse in recent-onset psychosis prospective study. Br J Psychiatry 189 (2006), 137–143.
18. 18 Hardwick, S, King, LA, Home Office cannabis potency study 2008, 2008, Home Office Scientific Development Branch United Kingdom.
19. 19 Bhattacharyya, S, Crippa, JA, Allen, P, et al. Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69 (2012), 27–36.
20. 20 Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, et al. Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35 (2010), 764–774.
21. 21 Leweke, FM, Piomelli, D, Pahlisch, F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, 2012, e94.
22. 22 Baeza, I, Graell, M, Moreno, D, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAfirst episode of psychosisS study). Schizophr Res 113 (2009), 129–137.
23. 23 Manrique-Garcia, E, Zammit, S, Dalman, C, Hemmingsson, T, Andreasson, S, Allebeck, P, Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med 44 (2014), 2513–2521.
24. 24 Barrowclough, C, Marshall, M, Gregg, L, et al. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychol Med 44 (2014), 2749–2761.
25. 25 Wilson, RP, Bhattacharyya, S, Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: a systematic review. J Psychopharmacol 30 (2016), 99–111.